Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)

NCT02154425 is registered in ClinicalTrials.gov with UCB BIOSCIENCES, Inc. as lead sponsor.

NCT NCT02154425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02154425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Lead sponsor
UCB BIOSCIENCES, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
January 31, 2016
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, axial spondyloarthritis (axspa), crohn's disease, non-radiographic evidence-axspa, psoriatic arthritis, rheumatoid arthritis